Case study of remission in adults with immune thrombocytopenia following cessation of treatment with the thrombopoietin mimetic romiplostim†

Hematology

Volumn 21, Issue 4, 2016, Pages 257-262

  Bussel, James B ^a   Wang, Xuena ^b   Lopez, Angela ^b   Eisen, Melissa ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b AMGEN INC   (United States)

Author keywords

Platelets; Remission; Thrombopoietin; Thrombopoietin receptor agonist

Indexed keywords

ROMIPLOSTIM; FC RECEPTOR; HYBRID PROTEIN; THROMBOPOIETIN;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL TRIAL (TOPIC); EPISTAXIS; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEMATURIA; HEMOPTYSIS; HUMAN; LUNG HEMORRHAGE; MAJOR CLINICAL STUDY; MIDDLE AGED; OPEN STUDY; PETECHIA; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PURPURA; REMISSION; SPLENECTOMY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; VAGINA BLEEDING; BLOOD; CONTROLLED STUDY; FEMALE; MALE; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECEPTORS, FC; RECOMBINANT FUSION PROTEINS; REMISSION INDUCTION; THROMBOPOIETIN;

EID: 84983445479     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/1607845415Y.0000000041     Document Type: Article

References (27)

1. F.Rodeghiero, R.Stasi, A.Giagounidis, J.F.Viallard, B.Godeau, I.Pabinger, Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia:a pooled analysis of 13 clinical trials. Eur J Haematol. 2013;91(5):423–36. doi:10.1111/ejh.12181
2. J.B.Bussel, F.Rodeghiero, R.M.Lyons, B.Firstenberg, J.Joseph, C.M.Kessler, Sustained hemostatic platelet counts in adults with immune thrombocytopenia (ITP) following cessation of treatment with the TPO receptor agonist romiplostim:report of 9 cases. Blood (ASH Annual Meeting Abstracts) 2011;118(21):3281.
3. D.J.Kuter, J.B.Bussel, R.M.Lyons, V.Pullarkat, T.B.Gernsheimer, F.M.Senecal, Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura:a double-blind randomised controlled trial. Lancet 2008;371(9610):395–403. doi:10.1016/S0140-6736(08)60203-2
4. A.Newland, M.T.Caulier, M.Kappers-Klunne, M.R.Schipperus, F.Lefrere, J.J.Zwaginga, An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura. Br J Haematol. 2006;135(4):547–53. doi:10.1111/j.1365-2141.2006.06339.x
5. M.Khellaf, M.Michel, P.Quittet, J.F.Viallard, M.Alexis, F.Roudot-Thoraval, Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice:2-year results of 72 adults in a romiplostim compassionate-use program. Blood 2011;118(16):4338–45. doi:10.1182/blood-2011-03-340166
6. A.A.Baxley, J.N.George, D.Terrell, M.Moorman, J.L.Holter. A case report of long-term complete remission following cessation of romiplostim dosing in a previously severe ITP patient. J Clin Oncol (ASCO Annual Meeting Abstracts) 2012;30:e17001.
7. F.Biondo, C.Santoro, E.Baldacci, A.Leporace, R.Foa, M.G.Mazzucconi. Persistent response after romiplostim discontinuation in patients affected by primary thrombocytopenia. Haematologica (EHA Annual Congress Abstracts) 2012;97(Suppl 1):428.
8. B.Ghadaki, I.Nazi, J.G.Kelton, D.M.Arnold. Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists. Transfusion 2013;53(11):2807–12. doi:10.1111/trf.12139
9. F.Iuliano, A.Perricelli, E.Iuliano, S.Infusino, A.Pomillo, M.Luci, Platelet kinetic study (PKS) may early identify a subset of patients with immune thrombocytopenia (ITP) probably cured by romiplostim. Two years follow-up. Blood (ASH Annual Meeting Abstracts) 2012;120(21):1099.
10. M.Perera, A.Suarez, H.Luzardo, J.Lopez, T.Molero. Spontaneous remission after a year of romiplostim in an adult patient with refractory primary immune thrombocytopenia. Ann Hematol. 2012;91(9):1497–8. doi:10.1007/s00277-012-1437-y
11. Y.Ramos, M.Perera, J.Lopez, A.Suarez, M.Gordillo, D.Fiallo, Is it feasible to discontinue treatment with romiplostim in ITP patients with maintained complete response? Haematologica (EHA Annual Congress Abstracts) 2012;97(Suppl 1):689.
12. E.Vlachaki, V.Papageorgiou, F.Klonizakis, M.Spandonidou, S.Chisan, E.Vetsiou, Total remission of severe immune thrombocytopenia after short term treatment with romiplostim. Hematol Rep. 2011;3(3):e20. doi:10.4081/hr.2011.e20
13. M.Mahevas, O.Fain, M.Ebbo, F.Roudot-Thoraval, N.Limal, M.Khellaf, The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study. Br J Haematol. 2014;165:865–9. doi:10.1111/bjh.12888
14. A.Janssens, F.Rodeghiero, D.Anderson, B.Chong, Z.Boda, I.Pabinger, Results from a phase IV open-label study evaluating changes in bone marrow morphology in adult immune thrombocytopenia (ITP) patients receiving romiplostim:analysis of the 1- and 2-year romiplostim cohorts. Blood (ASH Annual Meeting Abstracts) 2013;122(21):2312.
15. A.Janssens, M.D.Tarantino, R.Bird, M.G.Mazzucconi, R.V.V.Boccia, M.F.Lopez-Fernandez, Final results from an international, multi-center, single-arm study evaluating the safety and efficacy of romiplostim in adults with primary immune thrombocytopenia (ITP). Blood (ASH Annual Meeting Abstracts) 2011;118(21):3279.
16. D.J.Kuter, J.B.Bussel, A.Newland, J.S.Wasser, R.M.Lyons, J.N.George, Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia:safety and efficacy. Br J Haematol. 2013;161(3):411–23. doi:10.1111/bjh.12260
17. D.J.Kuter, M.Rummel, R.Boccia, B.G.Macik, I.Pabinger, D.Selleslag, Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med. 2010;363(20):1889–99. doi:10.1056/NEJMoa1002625
18. Y.Shirasugi, K.Ando, K.Miyazaki, Y.Tomiyama, K.Iwato, S.Okamoto, An open-label extension study evaluating the safety and efficacy of romiplostim for up to 3.5 years in thrombocytopenic Japanese patients with immune thrombocytopenic purpura (ITP). Int J Hematol. 2012;95(6):652–9. doi:10.1007/s12185-012-1065-2
19. Y.Shirasugi, K.Ando, K.Miyazaki, Y.Tomiyama, S.Okamoto, M.Kurokawa, Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients:a double-blind, randomized phase III clinical trial. Int J Hematol. 2011;94(1):71–80. doi:10.1007/s12185-011-0886-8
20. D.Provan, R.Stasi, A.C.Newland, V.S.Blanchette, P.Bolton-Maggs, J.B.Bussel, International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010;115(2):168–86. doi:10.1182/blood-2009-06-225565
21. T.Sailer, K.Lechner, S.Panzer, P.A.Kyrle, I.Pabinger. The course of severe autoimmune thrombocytopenia in patients not undergoing splenectomy. Haematologica 2006;91(8):1041–5.
22. W.Bao, J.B.Bussel, S.Heck, W.He, M.Karpoff, N.Boulad, Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents. Blood 2010;116(22):4639–45. doi:10.1182/blood-2010-04-281717
23. B.H.Chong. ITP:Tregs come to the rescue. Blood 2010;116(22):4388–90. doi:10.1182/blood-2010-09-302364
24. U.Johansson, M.G.Macey, D.Kenny, A.B.Provan, A.C.Newland. The role of natural killer T (NKT) cells in immune thrombocytopenia:is strong in vitro NKT cell activity related to the development of remission? Br J Haematol. 2005;129(4):564–5. doi:10.1111/j.1365-2141.2005.05495.x
25. X.Li, H.Zhong, W.Bao, N.Boulad, J.Evangelista, M.A.Haider, Defective regulatory B-cell compartment in patients with immune thrombocytopenia. Blood 2012;120(16):3318–25. doi:10.1182/blood-2012-05-432575
26. J.Peng, S.Liu, X.Liu, Q.Feng, H.Zhou, M.Hou. Thrombopoietin receptor agonists shifts the balance of Fcgamma receptors towards the inhibitory Fcgamma receptor IIB on monocytes in immune thrombocytopenia. Haematologica (EHA Annual Congress Abstracts) 2014;99(S1):232.
27. R.Stasi, A.Newland, B.Godeau, V.Priego, J.-F.Viallard, M.F.Lopez Fernandez, An interim analysis of a phase 2, single-arm study of platelet responses and remission rates in patients with immune thrombocytopenia (ITP) receiving romiplostim. Blood (ASH Annual Meeting Abstracts) 2013;122(21):1074.